The Biosimilars Council agrees with the FDA's position that data from a switching study or studies may no longer be necessary to support licensure of interchangeable biosimilar medicines.
The Guidance would support biologic drug competition, increase patient access to biosimilars and lower healthcare costs for patients, the FTC’s comment says.